Nociception

Hybrid/Virtual/Decentralized Clinical Trials Market Outlook Report 2021: Hybrid Trial Use and Experience, Provider Selection, Provider Perceptions, Future Predictions, Study Data - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021

The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities.

Key Points: 
  • The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities.
  • The publisher surveyed 109 respondents at sponsors and CROs regarding their experiences with hybrid trials and providers of these services.
  • Though not all reported a smooth, pain-free experience, nearly two-thirds of respondents came away with a positive overall impression of hybrid trials.
  • 83% of respondents expect that the hybrid trial model will be used more frequently than the traditional trial model three years from now.

SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study

Retrieved on: 
Monday, August 2, 2021

The study, "An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat hind paw incision model," was designed to help assess the potential of SCI-160, the Company's proprietary compound.

Key Points: 
  • The study, "An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat hind paw incision model," was designed to help assess the potential of SCI-160, the Company's proprietary compound.
  • Dr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented, "We are thrilled by this report; the findings corroborate results of previous SCI-160 pre-clinical studies.
  • The global postoperative pain management market is expected to account for $45 billion by 2026.
  • In the first study, neuropathic pain reversal experiments, injections were administered on Day 7 after nerve injury.

Dr. Trey Mouch Joins Central Texas Pain Center in Austin and Bee Cave

Retrieved on: 
Thursday, July 29, 2021

AUSTIN, Texas, July 29, 2021 /PRNewswire/ --Central Texas Pain Center is pleased to announce that Dr. Trey Mouch has joined the Central Texas Pain Center team after finishing his interventional pain fellowship at Weill Cornell Medical Center, Memorial Sloan-Kettering Cancer Center and Hospital for Special Surgery in New York.Dr.

Key Points: 
  • AUSTIN, Texas, July 29, 2021 /PRNewswire/ --Central Texas Pain Center is pleased to announce that Dr. Trey Mouch has joined the Central Texas Pain Center team after finishing his interventional pain fellowship at Weill Cornell Medical Center, Memorial Sloan-Kettering Cancer Center and Hospital for Special Surgery in New York.Dr.
  • Mouch will be providing patient care for Central Texas Pain Center in the rapidly growing Central and South Austin and Bee Cave neighborhoods of Austin, TX.
  • A native of Dallas, Texas, Dr. Mouch completed medical school at the University of Texas Health Science Center San Antonio.He has special interests in cancer pain, peripheral nerve therapies, and minimally invasive spinal therapy, including spinal cord stimulation and spinal decompression Therapies.
  • In addition, he firmly believes in a personalized and multidisciplinary approach to pain management to reduce patients' level of pain and increase their quality of life.

Branded Legacy, Inc. Launches New Delta 8 Product Line

Retrieved on: 
Wednesday, July 28, 2021

The Company adds the highly demanded Delta 8 products to its portfolio under Spikes CBDX brand.

Key Points: 
  • The Company adds the highly demanded Delta 8 products to its portfolio under Spikes CBDX brand.
  • Branded Legacys Vice President, Matthew Nichols quotes, Many of the retailers our sales team has contacted have requested Delta 8, and now we can fulfill this demand.
  • About Spikes CBDx: Spikes CBDx is a line of CBD products designed to assist athletes perform better, recover faster, and avoid injuries.
  • The CBD line also targets individuals who are looking for pain relief, better sleep, faster recovery and lowering inflammation.

Steven P. Cohen, Chief of Pain Medicine at Johns Hopkins, Joins Releviate Therapeutics as Head of Its Scientific Advisory Board

Retrieved on: 
Tuesday, July 27, 2021

As head of the scientific advisory board, Cohen will provide high-level scientific oversight and lead strategy on the companys therapeutic pipeline and clinical trials.

Key Points: 
  • As head of the scientific advisory board, Cohen will provide high-level scientific oversight and lead strategy on the companys therapeutic pipeline and clinical trials.
  • View the full release here: https://www.businesswire.com/news/home/20210727005141/en/
    Dr. Steven P. Cohen joins Releviate Therapeutics as head of its scientific advisory board.
  • We are honored to welcome Steven to our scientific advisory board, said Jacqueline Townsend Konstanturos, chairman of Releviate Therapeutics.
  • Unlike traditional neuropathic pain medication strategies, Releviate Therapeutics directly targets pain with antibodies whose development is rooted in actual pain pathophysiology.

XRHealth and Reducept Offer Patients Virtual Reality Therapy for Pain Management

Retrieved on: 
Monday, July 26, 2021

BOSTON, July 26, 2021 /PRNewswire/ -- XRHealth ,the leader in extended reality and therapeutic applications,announced today that they are working with Reducept to expand their offering to patients for virtual reality therapy for pain management.

Key Points: 
  • BOSTON, July 26, 2021 /PRNewswire/ -- XRHealth ,the leader in extended reality and therapeutic applications,announced today that they are working with Reducept to expand their offering to patients for virtual reality therapy for pain management.
  • The virtual reality technology provides exercises that train people suffering from chronic pain on how to gain control over pain, potentially reducing the need for medication.
  • The Reducept VR Game trains the users' brain to create its own pain medication via digital psychological pain treatment.
  • XRHealth operates state-of-the-art therapeutic care Virtual Clinics, utilizing proprietary FDA and CE registered medical Extended Reality (XR) technology (virtual and augmented reality).

The Gulf Pain Management Drugs Industry is Expected to Reach $1+ Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 23, 2021

The "Gulf Pain Management Drugs Market by Drug Class, Indication, Pain Type: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gulf Pain Management Drugs Market by Drug Class, Indication, Pain Type: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Gulf Pain Management Drugs Market was valued at $851.08 million in 2019, and is projected to reach $1,047.91 million by 2027, registering a CAGR of 3.2%.
  • The length of the pain would range from acute pain for short term to chronic pain for long term.
  • The Gulf pain management drugs market is segmented on the basis of drug class, indication, pain type, and region.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Retrieved on: 
Wednesday, July 21, 2021

Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Retrieved on: 
Wednesday, July 21, 2021

NEW YORK, July 21, 2021 /PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4%  and 20.6% of the adult population respectively. As psychedelics gain more recognition, companies such as Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), Seelos Therapeutics (NASDAQ:SEEL), Numinus Wellness Inc. (TSXV:NUMI) (OTC:LKYSF), Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED), and Mydecine Innovations Group Inc. (NEO:MYCO) (OTCPK:MYCOF) are engaging in research initiatives to develop psychedelic-assisted therapies for different mental illnesses and chronic pain conditions.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Canada’s surgery backlog could lead to wave of new chronic pain and opioid dependencies

Retrieved on: 
Wednesday, July 21, 2021

TORONTO, July 21, 2021 (GLOBE NEWSWIRE) -- As Canada’s vaccination rates climb and hospitals begin to tackle the mountain of postponed surgeries due to the pandemic, we are facing an echo epidemic of new chronic pain sufferers. Studies show that roughly 30 per cent of those undergoing surgery will go on to develop chronic pain, and about 25 per cent of all chronic pain conditions originate from surgical procedures.1,2 This has a detrimental effect on families, communities and the healthcare system. However, with recent innovations in genetic testing this does not have to be the fate for the thousands of Canadians who are about to have surgery.

Key Points: 
  • Studies show that roughly 30 per cent of those undergoing surgery will go on to develop chronic pain, and about 25 per cent of all chronic pain conditions originate from surgical procedures.1,2 This has a detrimental effect on families, communities and the healthcare system.
  • However, with recent innovations in genetic testing this does not have to be the fate for the thousands of Canadians who are about to have surgery.
  • The risk of chronic pain following surgery is high.
  • The risk may be further compounded by the current echo pandemic of mental health issues, as depression and anxiety significantly increase the risk of developing chronic pain after surgery.